Showing results (531-540 of 9,400) with videos related to

Sort By:
Pageof 940
Clinical Pharmacology and Therapeutics|August 8, 2006
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart diseaseMaria G Sciulli, Giulia Renda, Marta L Capone, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavirGerd Mikus, Verena Schöwel, Magdalena Drzewinska, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjectsManon J van der Lee, Lara Dawood, Hadewych J M ter Hofstede, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failureW Kirch, A Halabi, H Hinrichsen
Clinical Pharmacology and Therapeutics|March 1, 1992
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery painJ A Forbes, W T Beaver, K F Jones, et al.
Clinical Pharmacology and Therapeutics|May 19, 2005
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevanceRheem A Totah, Allan E Rettie
Clinical Pharmacology and Therapeutics|December 14, 2004
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivoTatsuki Fukami, Miki Nakajima, Ryoko Yoshida, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38Virginie Charasson, Ricardo Bellott, Delphine Meynard, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertensionIssam Zineh, Amber L Beitelshees, Andrea Gaedigk, et al.
Pageof 940